Zydus Lifesciences Share Price Target 2025, 2026, 2030, 2040, 2050

Zydus Lifesciences is a large Indian medicine company. It makes many health products like regular medicines, vaccines, new types of medicines called biosimilars, ingredients for medicines, animal health products, and wellness items. The company has factories in India, Brazil, and the UK and sells its products in countries like the US, Europe, and others. It focuses on research to make new and better medicines and works to provide good-quality, affordable healthcare to people everywhere.

What is Zydus Lifesciences Ltd NSE: ZYDUSLIFE?

Zydus Lifesciences, established in 1952 in Ahmedabad, India, by Dr Ramanbhai Patel. It is a large Indian medicine company. It makes and sells many types of health products like regular medicines, special medicines, vaccines, medicine ingredients, and wellness products. The company also creates new and advanced medicines. It has factories in India and other countries and sells its products worldwide, including in the US, Europe, and Africa, to provide good-quality healthcare to help people stay healthy.

Zydus Lifesciences Share Price Target

Zydus Lifesciences Share Price Target 2025

Originally, the company was called Cadila Healthcare. In February 2022, it changed its name to Zydus Lifesciences to give itself a fresh identity for the future. This new name shows the company’s bigger plan, not just making regular medicines, but becoming a global healthcare company. It works in many areas like medicines, vaccines, advanced biologic treatments, and wellness products. In 2025, its share price target would be ₹1059, as per stock market analysts.

According to stock market analysts, its share price would be between ₹795 to ₹1059 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	795	1059

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	891	1027
February	855	1026
March	859	939
April	795	949
May	859	934
June	917	995
July	951	1015
August	919	1029
September	972	1059
October	973	1017
November	920	998
December	868	1014

Zydus Lifesciences Share Price Target 2026

It has factories and research centres in states like Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. This wide presence helps Zydus cover different types of health needs and ensures that medicines are made, tested, and delivered properly. Having many plants allows the company to manage work efficiently, reach more people, and continue production even if one plant has a problem. It also lets it produce a variety of products, from medicine ingredients to finished medicines and wellness items. In 2026, its share price target would be ₹1288, as per stock market analysts.

According to stock market analysts, its share price would be between ₹980 to ₹1288 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	980	1288

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	980	1090
February	991	1112
March	1010	1127
April	1023	1142
May	1034	1153
June	1045	1167
July	1057	1178
August	1068	1190
September	1072	1221
October	1084	1235
November	1121	1265
December	1140	1288

Share Price Target 2027

It handles almost every step in making and delivering medicines and health products. The process starts with research in labs, then moves to making drug ingredients (APIs), producing the final medicines like tablets and injections, and finally distributing them to markets. Managing all these steps helps it to keep high quality, reliability, and efficiency. It also allows the company to respond quickly to what the market needs, increase production when required, and ensure a steady supply. In 2027, its share price target would be ₹1506, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1240 to ₹1506 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	1240	1506

Share Price Target 2028

The company spends a lot on research and development. It has many scientists working at different centres to discover and develop new medicines, biosimilars, vaccines, and advanced therapies. This focus helps the company create new chemical drugs and innovative treatments, not just copy existing ones. It can meet medical needs that are not fully addressed and stay ahead in the global healthcare industry by putting research first. This work helps produce medicines that improve people’s lives worldwide while keeping the company competitive in a fast-changing market. In 2028, its share price target would be ₹1721, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1471 to ₹1721 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	1471	1721

Share Price Target 2029

It has created biologics, biosimilars, and vaccines as part of its research and innovation. Its biologics division works on complex medicines that treat serious illnesses. The company also produces vaccines and advanced biologic treatments. These products make important treatments available that might otherwise be too expensive or hard to get in some markets. Producing biosimilars and vaccines helps more people get access to healthcare. In 2029, its share price target would be ₹1917, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1678 to ₹1917 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	1678	1917

Zydus Lifesciences share price Target 2030

It owns more than 30 manufacturing plants around the world. These factories are in India and other countries, which gives the company the ability to produce medicines on a large scale. The plants make many types of products, including finished medicines, drug ingredients (APIs), biologics, vaccines, animal health products, and wellness items. This wide production capability helps it to meet demand globally, maintain a steady supply, and manage large-scale production efficiently. In 2030, its share price target would be ₹2152, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1887 to ₹2152 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	1887	2152

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1887	2021
February	1900	2043
March	1917	2058
April	1925	2074
May	1935	2080
June	1949	2089
July	1965	2099
August	1982	2107
September	2004	2114
October	2012	2125
November	2027	2137
December	2050	2152

Share Price Target 2040

It is one of the top pharmaceutical companies. Its wide product range, strong production capacity, and research work have helped it gain a large share of the domestic market. The company works in many health areas, treating both common and serious illnesses. By keeping quality high and prices reasonable, it has become a trusted brand for patients, doctors, and hospitals. Its strong position in India also supports its growth in other countries, allowing it to export products and build partnerships internationally. In 2040, its share price target would be ₹3344, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3121 to ₹3344 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	3121	3344

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3121	3230
February	3130	3242
March	3142	3255
April	3157	3274
May	3174	3289
June	3185	3299
July	3200	3314
August	3209	3320
September	3221	3334
October	3235	3342
November	3248	3359
December	3268	3378

Share Price Target 2050

It wants to provide complete healthcare solutions. It covers everything from simple medicines to advanced biologics, vaccines, wellness products, and animal health items. The company makes sure that people from different income levels can get good healthcare by offering affordable options. Its approach from research to production to delivery helps make healthcare reliable and available to more people. It focuses on improving patient care and supporting healthcare systems worldwide. In 2050, its share price target would be ₹4702, as per stock market analysts.

According to stock market analysts, its share price would be between ₹4459 to ₹4702 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	4459	4702

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	4459	4578
February	4467	4599
March	4478	4621
April	4490	4637
May	4512	4656
June	4525	4678
July	4538	4690
August	4549	4711
September	4562	4725
October	4589	4754
November	4632	4778
December	4650	4790

Should I buy Zydus Lifesciences stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	795	1059
2026	980	1288
2028	1471	1721
2028	1471	1721
2029	1678	1917
2030	1887	2152
2040	3121	3344
2050	4459	4702

It is a strong and well-established healthcare company. It makes many types of products, like regular medicines, advanced medicines, vaccines, and wellness items, and sells them in India and other countries. The company spends a lot on research and has many factories, which gives it a chance to grow more in the future. But there are some risks, like competition from other companies, government rules, and challenges with new medicines or expanding globally. Overall, it can be a good long-term investment for people who are ready for some ups and downs in the market.

Zydus Lifesciences earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	14,253	14,404	15,110	17,237	19,547	23,242	24,494
Expenses +	11,455	11,013	11,768	13,378	14,163	16,183	16,876
Operating Profit	2,798	3,391	3,342	3,860	5,384	7,058	7,617
OPM %	20%	24%	22%	22%	28%	30%	31%
Other Income +	-264	-231	2,581	-422	293	50	148
Interest	342	159	127	130	81	166	295
Depreciation	696	670	713	723	764	916	1,007
Profit before tax	1,495	2,331	5,084	2,585	4,832	6,027	6,464
Tax %	21%	8%	10%	23%	20%	23%
Net Profit +	1,204	2,185	4,618	2,092	3,973	4,673	5,030
EPS in Rs	11.49	20.84	43.83	19.37	38.36	44.97	48.90
Dividend Payout %	30%	17%	6%	31%	8%	24%	—

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
18.89	3.53	1.19%	36.28	5.73	0.60%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Zydus Lifesciences Ltd	20.54	3.53	1.19%
Sun Pharmaceutical Industries Ltd	39.20	5.91	0.90%
Torrent Pharmaceuticals Ltd	67.19	16.92	0.84%
Cipla Ltd	22.84	3.85	1.07%

Is Zydus Lifesciences stock good to buy? (bull case & bear case)

Bull Case:

• In Q2 FY2025‑26, it made ₹61,232 million in revenue, which is about 17% more than last year, showing the company is growing.
• In the same quarter, its net profit increased 38% to ₹12,586 million, which means it is earning more money than before.
• Its EBITDA for Q2 FY26 rose to ₹20,158 million, and EBITDA margin improved to 32.9%, which shows the company is managing costs well and earning efficiently.
• It has negative net debt (net cash), meaning it owes very little and has enough money to invest in research, new products, or global expansion.
• The company works in many areas generic drugs, branded medicines, biologics/biosimilars, vaccines, wellness products, and sells in India and other countries.
• Because of strong growth, profits, and a wide business base, it could be a good choice for medium- to long-term investors who want a growing company.

Bear Case:

• Even though Q2 results are strong, the pharmaceutical industry is very competitive. Prices for generics and regulations in export markets may reduce profits.
• Global operations make it sensitive to currency changes, foreign regulations, and slow demand abroad, which could hurt revenue and profits.
• Some past quarters had revenue growth without matching profit growth, meaning high sales don’t always mean more earnings.

Conclusion

It makes many health products like regular medicines, advanced medicines, vaccines, and wellness items, and sells them in India and other countries. The company has many factories and focuses a lot on research to create new and better medicines that are affordable. Because it works in many areas, has a global presence, and is growing steadily, it can be a good long-term investment for people who can handle some ups and downs in the market.

FAQs